



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/613,092	07/10/2000	Edwin W. Ades	68430	9419

7590 07/03/2002
Gwendolyn D. SPRATT, ESQ.
Needle & Rosenberg, P.C.
The Candler Bldg, Suite 1200
127 Peachtree St NE
Atlanta, GA 30303-1811

EXAMINER

DEVI, SARVAMANGALA J N

ART UNIT	PAPER NUMBER
----------	--------------

1645

DATE MAILED: 07/03/2002

10

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.
09/613,092

Applicant(s)
Ades et al.

Examiner
S. Devi, Ph.D.

Art Unit
1645



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE one MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on Oct 15, 2001.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-20 ~~is/are~~ are pending in the application.
- 4a) Of the above, claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claims 1-20 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
*See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 6) ☐ Other:

Election/Restriction

- 1) Claims 1-20 are pending in the application and are under prosecution.
- 2) **Please Note:** In an effort to enhance communication with our customers and reduce processing time, Group 1640 is running a Fax Response Pilot for Written Restriction Requirements. A dedicated Fax machine is in place to receive your responses. The Fax number is 703-308-4315. A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Pilot program. If you have any questions or suggestions please contact Paula Hutzell, Ph.D., Supervisory Patent Examiner at Paula.Hutzell@uspto.gov or 703-308-4310. Thank you in advance for allowing us to enhance our customer service. Please limit the use of this dedicated Fax number to responses to Written Restrictions.
- 3) Restriction to one of the following inventions is required under 35 U.S.C. 121:
 1. Claims 2 and 3, drawn to a multiple antigenic peptide comprising SEQ ID NO: 5, classified in class 530, subclass 300.
 2. Claims 2 and 4, drawn to a multiple antigenic peptide comprising SEQ ID NO: 6, classified in class 530, subclass 300.
 3. Claims 2 and 5, drawn to a multiple antigenic peptide comprising SEQ ID NO: 7, classified in class 530, subclass 300.
 4. Claims 2 and 6, drawn to a multiple antigenic peptide comprising SEQ ID NO: 8, classified in class 530, subclass 300.
 5. Claims 2 and 7, drawn to a multiple antigenic peptide comprising SEQ ID NO: 9, classified in class 530, subclass 300.
 6. Claims 2 and 10, drawn to a multiple antigenic peptide comprising SEQ ID NO: 10, classified in class 530, subclass 300.
 7. Claim 9, drawn to a multiple antigenic peptide comprising SEQ ID NO: 5 and 6, classified in class 424, subclass 190.1.
 8. Claim 10, drawn to a multiple antigenic peptide comprising SEQ ID NO: 5 and 9, classified in class 424, subclass 190.1.
 9. Claim 11, drawn to a multiple antigenic peptide comprising SEQ ID NO: 5, 6 and 7, classified in class 424, subclass 190.1.

Serial Number 09/613,092
Art Unit: 1645

10. Claim 12, drawn to a multiple antigenic peptide comprising SEQ ID NO: 5, 9 and 10, classified in class 424, subclass 190.1.
11. Claims 13 and 14, drawn to a lipidated peptide, classified in class 530, subclass 300.
12. Claim 16, drawn to a method of conferring protective immunity by administering a composition comprising SEQ ID NO: 5, classified in class 424, subclass 244.1.
13. Claim 17, drawn to a method of conferring protective immunity by administering a composition comprising SEQ ID NO: 6, classified in class 424, subclass 244.1.
14. Claim 18, drawn to a method of conferring protective immunity by administering a composition comprising SEQ ID NO: 7, classified in class 424, subclass 244.1.
15. Claim 19, drawn to a method of conferring protective immunity by administering a composition comprising SEQ ID NO: 5, 6 and 7, classified in class 424, subclass 244.1.
16. Claim 20, drawn to a method of conferring protective immunity by administering a composition comprising SEQ ID NO: 5, 9 and 10, classified in class 424, subclass 244.1.

Claim 1 is considered a linking claim and would be joined with one of inventions 1 through 11, if elected.

Claim 15 is considered a linking claim and would be joined with one of inventions 12 through 16.

4) Inventions 1-16 are distinct from one another. Inventions 1-11 are drawn to different peptides or peptide combinations which are structurally, biologically or immunogenically distinct from one another. Although the inventions are classified under the same class/subclass, the claimed sequences require separate searches.

5) Inventions 1 and 12, inventions 2 and 13, inventions 3 and 14, inventions 9 and 15 and inventions 10 and 16, respectively, are related as product and process of using the product. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process of using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P 806.05(h)). In the instant case, the peptide or peptide combination can be used in a materially different process, for example, as an *in vitro* diagnostic reagent in a diagnostic assay.

The product of invention 11 is not required to practice the methods of inventions

inventions 12-16.

6) Inventions 7-10 and each of inventions 1, 2, 3, 5 and 6 and are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (M.P.E.P § 806.05(c)). In the instant case, the combination as claimed does not require the particulars of the peptide subcombination as claimed for patentability, because the combination peptide is an individually distinct amino acid sequence. And the subcombination peptide sequences are individually distinct sequences having their own separate utility, for example, as diagnostic antigens.

Because these inventions are distinct for the reasons given and have acquired a separate status in the art as shown by their different classifications/subclassifications and divergent subject matter, restriction for examination purposes as indicated is proper.

7) Applicants are advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 C.F.R. 1.143).

8) Applicants are reminded that upon cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filled petition under C.F.R. 1.48(b) and by the fee required under 37 C.F.R. 1.17(h).

9) Applicants are asked to note that upon election of claim(s) drawn to a product, the corresponding method claim(s) will be retained as pending claims pursuant to the rejoinder provisions of M.P.E.P 821.04 and will be withdrawn from consideration until such time as the subject matter of elected product claim(s) are deemed allowable. The Examiner in charge of the instant application will then determine if corresponding method claims include all of the limitations of the allowable product claim(s) prior to determining if rejoinder will be permitted under M.P.E.P 821.04.

Serial Number 09/613,092
Art Unit: 1645

10) Any inquiry concerning this communication or earlier communications from the Examiner should be directed to S. Devi, Ph.D., whose telephone number is (703) 308-9347. A message may be left on the Examiner's voice mail system. The Examiner can normally be reached on Monday to Friday from 7.15 a.m. to 4.15 p.m. except one day each bi-week which would be disclosed on the Examiner's voice mail system.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Lynette Smith, can be reached on (703) 309-3909. The fax phone number for this Group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

June, 2002


S. DEVI, PH.D.
PRIMARY EXAMINER



RESTRICTION ELECTION FACSIMILE TRANSMISSION

DATE:

FROM/ATTORNEY:

FIRM:

PAGES, INCLUDING COVERSHEET:

PHONE NUMBER:

TO EXAMINER:

ART UNIT:

SERIAL NUMBER:

FAX/TELECOPIER NUMBER: (703) 308-4315

**PLEASE NOTE: THIS FACSIMILE NUMBER IS TO BE USED ONLY
FOR RESPONSES TO RESTRICTIONS.**

COMMENTS: _____

IF YOU HAVE NOT RECEIVED ALL THE PAGES OF THIS TRANSMISSION, PLEASE CONTACT THE ATTORNEY AT THE TELEPHONE NUMBER LISTED ABOVE.

IN COMPLIANCE WITH 1096 OG 30, THE FILING DATE ACCORDED EACH OFFICIAL FAX TRANSMISSION WILL BE DETERMINED BY THE FAX MACHINE DATE STAMP FOUND ON THE LAST PAGE OF THE TRANSMISSION, UNLESS THAT DATE IS A SATURDAY, SUNDAY, OR FEDERAL HOLIDAY WITHIN THE DISTRICT OF COLUMBIA, IN WHICH CASE THE OFFICIAL DATE OF RECEIPT WILL BE THE NEXT BUSINESS DAY.

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAIN(S) INFORMATION FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THIS INFORMATION IS FOR THE USE OF THE INDIVIDUAL OR FIRM NAMED ON THIS SHEET. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION, OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS INFORMATION IS STRICTLY PROHIBITED. THE DOCUMENTS SHOULD BE RETURNED TO THE PATENT AND TRADEMARK OFFICE IMMEDIATELY. IF THIS FACSIMILE IS RECEIVED IN ERROR, PLEASE NOTIFY THE ATTORNEY LISTED HEREON IMMEDIATELY.